Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
基本信息
- 批准号:7614313
- 负责人:
- 金额:$ 16.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-15 至 2011-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdultAdverse effectsAgeBiologyBlast CellBloodBone MarrowCEBPA geneCancer and Leukemia Group BCharacteristicsChemotherapy-Oncologic ProcedureClassificationClinicalClinical ManagementCytogeneticsDetectionDiagnosisDiseaseEVI1 geneElderlyEmployee StrikesFLT3 geneFrequenciesFutureGene ExpressionGene Expression ProfileGene MutationGenesGoalsHematopoieticHeterogeneityIncidenceKaryotypeMLL geneMalignant - descriptorMolecularMolecular AbnormalityMolecular ProfilingMutationMyelogenousNPM1 geneOblimersenOutcomePatientsPhase III Clinical TrialsPopulationPredictive ValuePrognostic FactorPrognostic MarkerProtocols documentationRandomizedResearchRiskStratificationSubgroupSupportive careTherapeuticTherapeutic InterventionTherapy Clinical TrialsUnited Statesbasecell growthchemotherapycohorthuman old age (65+)improvedmolecular markernew therapeutic targetnovelnovel strategiesolder patientprognosticpublic health relevanceresponsetreatment responsetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Recent molecular analyses have revealed at diagnosis, a striking heterogeneity with regard to the presence of acquired gene mutations and changes in gene expression in patients with acute myeloid leukemia (AML) and a normal karyotype, the largest cytogenetic subset (i.e., 40-49%) of AML. Multiple submicroscopic genetic alterations with prognostic significance have been discovered, including internal tandem duplication of the FLT3 gene, partial tandem duplication of the MLL gene, mutations in the NPM1 and CEBPA genes high expression of the ERG and BAALC genes. Application of gene-expression profiling has also identified a gene-expression signature that appears to separate cytogenetically normal AML patients into prognostic subgroups. These and similar future findings are likely to have a major impact on the clinical management of
cytogenetically normal AML, not only in prognostication but also in selection of appropriate treatment, since many of the identified genetic alterations constitute or will potentially become targets for specific therapeutic intervention. However, most of the studies that have identified and validated these prognostic markers in younger patients (i.e., <60 years), while their predicting value in older patients (>60 years) with normal cytogenetics AML remains to be fully evaluated. This issue is of paramount importance as in the United States 12.6 AML cases per 100,000 are diagnosed if only adults >65 years are considered and the response rates of older AML patients are significantly worse than those of the younger patients. Although these differences could be related to overrepresentation of several clinical poor-prognostic factors, the contribution of distinct molecular markers in the older group remains to be fully evaluated in order to refine risk-adapted stratification strategies that allocate patients who are not likely to respond to conventional chemotherapy treatment, to investigational therapeutic trials. Using as a platform the Cancer and Leukemia Group B (CALGB) 10201 study, a multicenter phase III trial (CALGB) that randomized older AML patients to intensive chemotherapy w/wo the Bcl-2 antisense Genasense, we propose to conduct definitive analyses that assess the frequency and predictive value of molecular abnormalities in older AML patients with normal cytogenetics. To achieved these goals we are proposing the following specific aims: 1) to determine in older AML patients with normal cytogenetics the frequency and the prognostic value of single-gene markers that have been already shown to be predictive of outcome in younger AML; 2) to identify microarray multi-gene expression signatures that correlate with clinical characteristics at diagnosis and outcome in older AML patients with normal cytogenetics; 3) to identify specific microarray multi-miR expression signatures that correlate with clinical characteristics at diagnosis and outcome in older AML patients with normal
cytogenetics.
PUBLIC HEALTH RELEVANCE: Acute myeloid leukemia (AML) is a malignant, heterogeneous disease characterized by proliferation with maturation arrest of myeloid blasts in bone marrow and blood. In the United States, the incidence of this disease in adults older than 65 years is elevated and the outcome with current treatment approaches is extremely dismal with <10% of the cases achieving long-term survival. Therefore, novel strategies are highly needed. Here, we propose to characterize older AML patients with normal cytogenetics, the largest subgroup of elderly AML (~50% of the entire elderly AML population) for specific molecular markers that can predict outcome. This approach will ultimately allow patients' stratification into risk-adapted treatments and give to those patients who are unlikely to be cured with standard approaches, the possibility to be treated on studies investigating novel compounds without having to suffer first the side effects of the currently used, but ineffective intensive chemotherapy regimens.
描述(由申请人提供):最近的分子分析显示,在诊断时,急性髓性白血病(AML)和正常核型患者中获得性基因突变和基因表达变化的存在显著的异质性,最大的细胞遗传学亚群(即,40-49%)的AML。已发现多种具有预后意义的亚显微遗传学改变,包括FLT 3基因的内部串联重复、MLL基因的部分串联重复、NPM 1和CEBPA基因突变以及ERG和BAALC基因的高表达。基因表达谱的应用也确定了一个基因表达特征,似乎将细胞遗传学正常的AML患者分为预后亚组。这些和类似的未来发现可能会对临床管理产生重大影响,
细胞遗传学正常的AML,不仅在诊断上,而且在选择适当的治疗上,因为许多鉴定的遗传改变构成或可能成为特异性治疗干预的靶点。然而,大多数在年轻患者中鉴定和验证这些预后标志物的研究(即,<60岁),而其在细胞遗传学正常的老年AML患者(>60岁)中的预测价值仍有待充分评估。这一问题至关重要,因为在美国,如果仅考虑65岁以上的成年人,每100,000人中诊断出12.6例AML病例,老年AML患者的缓解率明显低于年轻患者。虽然这些差异可能与多个临床预后不良因素的过度表达有关,但老年组中不同分子标志物的贡献仍有待充分评估,以完善风险适应性分层策略,将不太可能对常规化疗治疗有反应的患者分配到研究性治疗试验中。使用癌症和白血病组B(CALGB)10201研究作为平台,这是一项多中心III期试验(CALGB),将老年AML患者随机分配至含Bcl-2反义Genasense的强化化疗组,我们建议进行确定性分析,评估细胞遗传学正常的老年AML患者中分子异常的频率和预测价值。为了实现这些目标,我们提出了以下具体目标:1)在具有正常细胞遗传学的老年AML患者中确定已经被证明可预测年轻AML结果的单基因标志物的频率和预后价值; 2)鉴定与具有正常细胞遗传学的老年AML患者的诊断和结果的临床特征相关的微阵列多基因表达特征; 3)鉴定与具有正常骨髓增生异常综合征的老年AML患者的诊断和结果的临床特征相关的特异性微阵列多miR表达特征,
细胞遗传学
公共卫生相关性:急性髓系白血病(acute myeloid leukemia,AML)是一种以骨髓和血液中的髓系原始细胞增殖和成熟停滞为特征的恶性异质性疾病。在美国,这种疾病在65岁以上的成年人中的发病率升高,目前治疗方法的结果非常令人沮丧,<10%的病例获得长期生存。因此,非常需要新的战略。在这里,我们建议对具有正常细胞遗传学的老年AML患者进行表征,这是老年AML中最大的亚组(约占整个老年AML人群的50%),可以预测结果的特定分子标志物。这种方法最终将允许患者分层为风险适应性治疗,并为那些不太可能用标准方法治愈的患者提供在研究新化合物的研究中进行治疗的可能性,而不必首先遭受目前使用的副作用,但无效的强化化疗方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUIDO MARCUCCI其他文献
GUIDO MARCUCCI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUIDO MARCUCCI', 18)}}的其他基金
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10367856 - 财政年份:2022
- 资助金额:
$ 16.88万 - 项目类别:
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10544734 - 财政年份:2022
- 资助金额:
$ 16.88万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10371023 - 财政年份:2020
- 资助金额:
$ 16.88万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10094210 - 财政年份:2020
- 资助金额:
$ 16.88万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10600088 - 财政年份:2020
- 资助金额:
$ 16.88万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8815267 - 财政年份:2011
- 资助金额:
$ 16.88万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8627134 - 财政年份:2011
- 资助金额:
$ 16.88万 - 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
- 批准号:
7471096 - 财政年份:2008
- 资助金额:
$ 16.88万 - 项目类别:
Pharmacologic modulation of chromatin remodeling in leu*
leu* 染色质重塑的药理学调节
- 批准号:
7096021 - 财政年份:2005
- 资助金额:
$ 16.88万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 16.88万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 16.88万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 16.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 16.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 16.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)